Download PDF
Journal of Pediatric Epilepsy 2015; 04(03): 130-136
DOI: 10.1055/s-0035-1558833
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Epilepsy in Adolescents: Rational Treatment and Considerations

Gregory B. Sharp
1   Departments of Pediatrics and Neurology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
› Author Affiliations
Further Information

Publication History

19 January 2015

20 January 2015

Publication Date:
17 August 2015 (online)

    Permissions and Reprints

Abstract

Human brain development is a dynamic process that proceeds from childhood through the adolescent period into adulthood both anatomically and functionally. Likewise, epilepsy follows a course of change. Childhood seizure disorders may change or remit, and other epilepsies may begin during adolescence. Care of the epilepsy patient should include new or further diagnostic testing that is appropriate for the individual patient, differentiation from other paroxysmal disorders, attention to psychosocial and behavioral concerns, and selection and management of appropriate antiepileptic drug therapy. Attention should also be placed on potential adverse effects that appropriate antiepileptic drugs may impart. Special consideration should be given to adolescent girls who should be considered of childbearing age during adolescence. When epilepsy is refractory to medical therapy, alternative therapies should be considered that include epilepsy surgery, vagus nerve stimulation, and specific diets such as ketogenic diet and modified Atkins diet that can be used to successfully treat epilepsy.

Keywords

adolescents - epilepsy - antiepileptic drugs
 

  • References

  • 1 Craiu D. What is special about the adolescent (JME) brain?. Epilepsy Behav 2013; 28 (Suppl. 01) S45-S51
    CrossrefPubMedGoogle Scholar
  • 2 Gogtay N, Giedd JN, Lusk L , et al. Dynamic mapping of human cortical development during childhood through early adulthood. Proc Natl Acad Sci U S A 2004; 101 (21) 8174-8179
    CrossrefPubMedGoogle Scholar
  • 3 Sowell ER, Trauner DA, Gamst A, Jernigan TL. Development of cortical and subcortical brain structures in childhood and adolescence: a structural MRI study. Dev Med Child Neurol 2002; 44 (1) 4-16
    CrossrefPubMedGoogle Scholar
  • 4 Tau GZ, Peterson BS. Normal development of brain circuits. Neuropsychopharmacology 2010; 35 (1) 147-168
    CrossrefPubMedGoogle Scholar
  • 5 Sowell ER, Delis D, Stiles J, Jernigan TL. Improved memory functioning and frontal lobe maturation between childhood and adolescence: a structural MRI study. J Int Neuropsychol Soc 2001; 7 (3) 312-322
    CrossrefPubMedGoogle Scholar
  • 6 Sowell ER, Peterson BS, Thompson PM, Welcome SE, Henkenius AL, Toga AW. Mapping cortical change across the human life span. Nat Neurosci 2003; 6 (3) 309-315
    CrossrefPubMedGoogle Scholar
  • 7 Sowell ER, Thompson PM, Holmes CJ, Jernigan TL, Toga AW. In vivo evidence for post-adolescent brain maturation in frontal and striatal regions. Nat Neurosci 1999; 2 (10) 859-861
    CrossrefPubMedGoogle Scholar
  • 8 Bava S, Thayer R, Jacobus J, Ward M, Jernigan TL, Tapert SF. Longitudinal characterization of white matter maturation during adolescence. Brain Res 2010; 1327: 38-46
    CrossrefPubMedGoogle Scholar
  • 9 Barnea-Goraly N, Menon V, Eckert M , et al. White matter development during childhood and adolescence: a cross-sectional diffusion tensor imaging study. Cereb Cortex 2005; 15 (12) 1848-1854
    CrossrefPubMedGoogle Scholar
  • 10 Giorgio A, Watkins KE, Douaud G , et al. Changes in white matter microstructure during adolescence. Neuroimage 2008; 39 (1) 52-61
    CrossrefPubMedGoogle Scholar
  • 11 Giorgio A, Watkins KE, Chadwick M , et al. Longitudinal changes in grey and white matter during adolescence. Neuroimage 2010; 49 (1) 94-103
    CrossrefPubMedGoogle Scholar
  • 12 Schmithorst VJ, Wilke M, Dardzinski BJ, Holland SK. Correlation of white matter diffusivity and anisotropy with age during childhood and adolescence: a cross-sectional diffusion-tensor MR imaging study. Radiology 2002; 222 (1) 212-218
    CrossrefPubMedGoogle Scholar
  • 13 Kretschmann HJ. Localisation of the corticospinal fibres in the internal capsule in man. J Anat 1988; 160: 219-225
    PubMedGoogle Scholar
  • 14 Wierenga L, Langen M, Ambrosino S , et al. Typical development of basal ganglia, hippocampus, amygdala and cerebellum from age 7 to 24. Neuroimage 2014; 96: 67-72
    CrossrefPubMedGoogle Scholar
  • 15 Gauthier CT, Duyme M, Zanca M, Capron C. Sex and performance level effects on brain activation during a verbal fluency task: a functional magnetic resonance imaging study. Cortex 2009; 45 (2) 164-176
    CrossrefPubMedGoogle Scholar
  • 16 Hamilton LS, Levitt JG, O'Neill J , et al. Reduced white matter integrity in attention-deficit hyperactivity disorder. Neuroreport 2008; 19 (17) 1705-1708
    CrossrefPubMedGoogle Scholar
  • 17 Jansen LA, Peugh LD, Roden WH, Ojemann JG. Impaired maturation of cortical GABA(A) receptor expression in pediatric epilepsy. Epilepsia 2010; 51 (8) 1456-1467
    CrossrefPubMedGoogle Scholar
  • 18 Escayg A, MacDonald BT, Meisler MH , et al. Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFS+2. Nat Genet 2000; 24 (4) 343-345
    CrossrefPubMedGoogle Scholar
  • 19 Claes L, Del-Favero J, Ceulemans B, Lagae L, Van Broeckhoven C, De Jonghe P. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet 2001; 68 (6) 1327-1332
    CrossrefPubMedGoogle Scholar
  • 20 Harkin LA, McMahon JM, Iona X , et al; Infantile Epileptic Encephalopathy Referral Consortium. The spectrum of SCN1A-related infantile epileptic encephalopathies. Brain 2007; 130 (Pt 3) 843-852
    CrossrefPubMedGoogle Scholar
  • 21 Zuberi SM, Brunklaus A, Birch R, Reavey E, Duncan J, Forbes GH. Genotype-phenotype associations in SCN1A-related epilepsies. Neurology 2011; 76 (7) 594-600
    CrossrefPubMedGoogle Scholar
  • 22 De Vivo DC, Trifiletti RR, Jacobson RI, Ronen GM, Behmand RA, Harik SI. Defective glucose transport across the blood-brain barrier as a cause of persistent hypoglycorrhachia, seizures, and developmental delay. N Engl J Med 1991; 325 (10) 703-709
    CrossrefPubMedGoogle Scholar
  • 23 Leen WG, Wevers RA, Kamsteeg EJ, Scheffer H, Verbeek MM, Willemsen MA. Cerebrospinal fluid analysis in the workup of GLUT1 deficiency syndrome: a systematic review. JAMA Neurol 2013; 70 (11) 1440-1444
    CrossrefPubMedGoogle Scholar
  • 24 Pong AW, Geary BR, Engelstad KM, Natarajan A, Yang H, De Vivo DC. Glucose transporter type I deficiency syndrome: epilepsy phenotypes and outcomes. Epilepsia 2012; 53 (9) 1503-1510
    CrossrefPubMedGoogle Scholar
  • 25 Suls A, Dedeken P, Goffin K , et al. Paroxysmal exercise-induced dyskinesia and epilepsy is due to mutations in SLC2A1, encoding the glucose transporter GLUT1. Brain 2008; 131 (Pt 7) 1831-1844
    CrossrefPubMedGoogle Scholar
  • 26 Klepper J. Glucose transporter deficiency syndrome (GLUT1DS) and the ketogenic diet. Epilepsia 2008; 49 (Suppl. 08) 46-49
    CrossrefPubMedGoogle Scholar
  • 27 Sulc V, Stykel S, Hanson DP , et al. Statistical SPECT processing in MRI-negative epilepsy surgery. Neurology 2014; 82 (11) 932-939
    CrossrefPubMedGoogle Scholar
  • 28 Bouma PA, Bovenkerk AC, Westendorp RG, Brouwer OF. The course of benign partial epilepsy of childhood with centrotemporal spikes: a meta-analysis. Neurology 1997; 48 (2) 430-437
    CrossrefPubMedGoogle Scholar
  • 29 Camfield CS, Berg A, Stephani U, Wirrell EC. Transition issues for benign epilepsy with centrotemporal spikes, nonlesional focal epilepsy in otherwise normal children, childhood absence epilepsy, and juvenile myoclonic epilepsy. Epilepsia 2014; 55 (Suppl. 03) 16-20
    CrossrefPubMedGoogle Scholar
  • 30 Wirrell EC, Camfield CS, Camfield PR, Gordon KE, Dooley JM. Long-term prognosis of typical childhood absence epilepsy: remission or progression to juvenile myoclonic epilepsy. Neurology 1996; 47 (4) 912-918
    CrossrefPubMedGoogle Scholar
  • 31 Trinka E, Baumgartner S, Unterberger I , et al. Long-term prognosis for childhood and juvenile absence epilepsy. J Neurol 2004; 251 (10) 1235-1241
    CrossrefPubMedGoogle Scholar
  • 32 Wirrell EC, Grossardt BR, So EL, Nickels KC. A population-based study of long-term outcomes of cryptogenic focal epilepsy in childhood: cryptogenic epilepsy is probably not symptomatic epilepsy. Epilepsia 2011; 52 (4) 738-745
    CrossrefPubMedGoogle Scholar
  • 33 Berg AT, Testa FM, Levy SR. Complete remission in nonsyndromic childhood-onset epilepsy. Ann Neurol 2011; 70 (4) 566-573
    CrossrefPubMedGoogle Scholar
  • 34 Schmidt D. AED discontinuation may be dangerous for seizure-free patients. J Neural Transm 2011; 118 (2) 183-186
    CrossrefPubMedGoogle Scholar
  • 35 French JA, Gazzola DM. Antiepileptic drug treatment: new drugs and new strategies. Continuum (Minneap Minn) 2013; 19 (3 Epilepsy): 643-655
    PubMedGoogle Scholar
  • 36 Harden CL, Meador KJ, Pennell PB , et al; American Academy of Neurology; American Epilepsy Society. Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009; 50 (5) 1237-1246
    CrossrefPubMedGoogle Scholar
  • 37 Holmes LB, Baldwin EJ, Smith CR , et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology 2008; 70 (22) 2152-2158
    CrossrefPubMedGoogle Scholar
  • 38 Foldvary-Schaefer N, Harden C, Herzog A, Falcone T. Hormones and seizures. Cleve Clin J Med 2004; 71 (Suppl. 02) S11-S18
    CrossrefPubMedGoogle Scholar
  • 39 Kwan P, Arzimanoglou A, Berg AT , et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010; 51 (6) 1069-1077
    CrossrefPubMedGoogle Scholar
  • 40 Henry TR. Therapeutic mechanisms of vagus nerve stimulation. Neurology 2002; 59 (6) (Suppl. 04) S3-S14
    PubMedGoogle Scholar
  • 41 Morris III GL, Gloss D, Buchhalter J, Mack KJ, Nickels K, Harden C. Evidence-based guideline update: vagus nerve stimulation for the treatment of epilepsy: report of the guideline development subcommittee of the American Academy of Neurology. Epilepsy Curr 2013; 13 (6) 297-303
    CrossrefPubMedGoogle Scholar
  • 42 Sun FT, Morrell MJ. The RNS System: responsive cortical stimulation for the treatment of refractory partial epilepsy. Expert Rev Med Devices 2014; 11 (6) 563-572
    CrossrefPubMedGoogle Scholar
  • 43 Wilder RM. The effects of ketonemia on course of epilepsy. Mayo Clin Proc 1921; 2: 307-308
    PubMedGoogle Scholar
  • 44 Lutas A, Yellen G. The ketogenic diet: metabolic influences on brain excitability and epilepsy. Trends Neurosci 2013; 36 (1) 32-40
    CrossrefPubMedGoogle Scholar
  • 45 Lefevre F, Aronson N. Ketogenic diet for the treatment of refractory epilepsy in children: A systematic review of efficacy. Pediatrics 2000; 105 (4) E46
    CrossrefPubMedGoogle Scholar
  • 46 Kossoff EH, Cervenka MC, Henry BJ, Haney CA, Turner Z. A decade of the modified Atkins diet (2003–2013): Results, insights, and future directions. Epilepsy Behav 2013; 29 (3) 437-442
    CrossrefPubMedGoogle Scholar
  • 47 Groesbeck DK, Bluml RM, Kossoff EH. Long-term use of the ketogenic diet in the treatment of epilepsy. Dev Med Child Neurol 2006; 48 (12) 978-981
    CrossrefPubMedGoogle Scholar
  • 48 Kossoff EH, Zupec-Kania BA, Amark PE , et al; Charlie Foundation, Practice Committee of the Child Neurology Society; Practice Committee of the Child Neurology Society; International Ketogenic Diet Study Group. Optimal clinical management of children receiving the ketogenic diet: recommendations of the International Ketogenic Diet Study Group. Epilepsia 2009; 50 (2) 304-317
    CrossrefPubMedGoogle Scholar
  • 49 Martinez CC, Pyzik PL, Kossoff EH. Discontinuing the ketogenic diet in seizure-free children: recurrence and risk factors. Epilepsia 2007; 48 (1) 187-190
    PubMedGoogle Scholar